PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
50 hedge funds and large institutions have $61.1M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 51 → 50 (-1)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
48% less capital invested
Capital invested by funds: $118M → $61.1M (-$57.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$747K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$618K |
| 3 |
Millennium Management
New York
|
+$451K |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$215K |
| 5 |
PTP
Platform Technology Partners
New York
|
+$159K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.19M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.09M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$559K |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$557K |
| 5 |
Goldman Sachs
New York
|
-$312K |
PHAS Hedge Fund Activity: Q1 2020 in Review
50 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q1 2020, worth a combined $61.1M — down 48% from $118M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PHAS positions and 8 closed out — a net gain of 1 holder — while 15 added to existing stakes and 18 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $747K. The largest seller was Farallon Capital Management, cutting an estimated $4.19M.
- 50 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q1 2020, down from 51 in Q4 2019.
- Funds reported $61.1M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q1 2020, down 48% quarter-over-quarter.
- 9 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 8 closed out, a net change of +1 holder.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Renaissance Technologies, an estimated $747K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Farallon Capital Management, an estimated $4.19M sold.
Based on aggregated 13F filings for Q1 2020.